ORBIMED ADVISORS LLC sold $5.3M of SION (indirect holdings)

ORBIMED ADVISORS LLC sold 115,844 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at $45.50 ($5.27M total) on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ORBIMED ADVISORS LLC
Published Jul 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SION
Neutral
medium confidence
Mentioned
$SION
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIONNeutralLow
01

Why it matters

Because the sale is pre-arranged, it is generally less informative about near-term company fundamentals. The main tradable angle is short-term sentiment around insider activity.

02

Market read

A $5.27M insider sale under a 10b5-1 plan is disclosed, which may slightly pressure sentiment but is unlikely to drive a fundamental repricing by itself.

03

What to watch

The article does not clarify whether the sale was part of a broader multi-tranche program, nor does it provide context on total holdings changes beyond the post-transaction share count.

Relevance 5/10Novelty 3/10Timing: filed July 2, 2026, covering a June 30 sale

Background

The article reports an SEC Form 4 insider transaction for Sionna Therapeutics, Inc. (SION) by ORBIMED ADVISORS LLC, marked as an indirect holding and executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$SIONNeutralMedium confidence
Context

ORBIMED ADVISORS LLC, a director of Sionna Therapeutics, sold 115,844 shares at $45.50 via a 10b5-1 plan, totaling about $5.27M.

Expected impact

Limited near-term impact expected; any effect is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 open-market sale with explicit 10b5-1 pre-arrangement, which typically reduces the informational content versus discretionary sales.

Market effects

No direct sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with perceived valuation risk, so traders may treat it as a mild bearish sentiment input.

Key entities

  • Sionna Therapeutics, Inc.

    Subject of the Form 4 insider transaction; director-related indirect holdings were reduced via an open-market sale.

  • ORBIMED ADVISORS LLC

    Reporter of the Form 4 transaction, selling shares as an indirect holding under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIONLowAI 8/10

Sionna Therapeutics 3Q 2026: EPS ($0.72) — 10-Q Summary

Sionna Therapeutics reported a wider net loss of $32.42M in Q3 2026, up 59.9% YoY, due to increased R&D and administrative expenses. The company selected SION-451 + SION-2222 for its dual combination program but will not advance SION-719 after a failed trial. It reduced its workforce by 46% and expects its cash runway to extend into 2H 2029.

$SIONMed

Sionna Therapeutics Reports Third Quarter 2026 Financial Results

Sionna Therapeutics, Inc. (SION) filed an SEC Form 8-K — Results of Operations and Financial Condition. Sionna Therapeutics Reports Third Quarter 2026 Financial Results Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027 Clinical and nonclinical data presented at 2026 NACFC support advance

$SIONMedAI 8/10

Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference

Sionna Therapeutics (Nasdaq: SION) will present data at the 2026 North American Cystic Fibrosis Conference. The company reported post hoc analyses of the PreciSION CF trial, showing an 8.6 mmol/L sweat chloride reduction with SION-719. Sionna plans to advance SION-451 + SION-2222 into a Phase 2a trial in early 2027. Preclinical data suggests potential benefits for a broad CF population.

$SIONMed

RA CAPITAL MANAGEMENT, L.P. (Kolchinsky Peter, Shah Rajeev M.) sold $21.8M of SION (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. sold 3,448,811 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at an average of $6.33 ($6.32–$7.46, $21.84M total) across 2 trades on 2026-09-17. Filed jointly with RA Capital Healthcare Fund LP (Director), RA Capital Nexus Fund, L.P. (Director), RA Capital Nexus Fund III, L.P. (Director), Kolchinsky Peter (Director) and Shah Rajeev M. (Director).

$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo